<Industry Awareness and Future Trends> The Reality of Clinical Trial Drug Supply During the COVID-19 Pandemic

Added to bookmarks
Bookmarks list

Bookmark has been removed
Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.
Free membership registration

last updated：Dec 10, 2020

Official site

A report on a survey conducted with 234 individuals engaged in clinical supply and operations regarding the advantages and potential barriers of DtP in current and future clinical trials.

The ideal model for remote clinical trials such as DtP and StP is to be flexible and accurately address the needs of patients and the protocol. With Catalent's "FlexDirect" Direct-to-Patient service, sponsors can make strategic choices flexibly. In addition to consistent supply support from Catalent, including traditional site shipments, site-to-patient shipments (StP), and direct-to-patient shipments (DtP), customized support for specific needs (such as emergency shipments) is also possible. Patient needs vary each time depending on the situation. This "FlexDirect" Direct-to-Patient service model allows for flexible responses to any situation. More detailed information is also available here: clinical.catalent.com/solutions/flexdirect-direct-to-patient-services/

Inquire About This Product

basic information

Catalent Pharma Solutions is a development and manufacturing partner for pharmaceuticals and health supplements. Headquartered in New Jersey, USA, we leverage an extensive global network with over 30 locations worldwide to assist in formulation across a diverse range of categories and dosage forms, from small molecule drugs to biopharmaceuticals, and from soft capsules to injectables. Our Japanese subsidiary, Catalent Japan Co., Ltd., has been in operation for over 40 years and has development and manufacturing capabilities for soft capsules of pharmaceuticals and health supplements at our Kakegawa plant in Shizuoka Prefecture. With 85 years of experience in soft capsule manufacturing technology, along with the expertise and achievements cultivated through long-term operations in Japan, our global network supports domestic and international know-how and information to assist in your formulation development and manufacturing. Dosage forms not manufactured in Japan can also be supported at our globally deployed manufacturing sites. Additionally, in Japan, the Kakegawa plant is equipped with a base for clinical trial-related services, offering a variety of services from project management to packaging, storage, and distribution of clinical trial drugs. We are also planning to open a GMP site in Shiga Prefecture soon.